Asset
RILUZOLE
AQUESTIVE THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03679975 | phase2 | terminated | 2018-04-04 | 2018-09-26 | Aquestive Therapeutics | Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS) |
| NCT03457753 | phase2 | withdrawn | 2018-03-01 | 2018-03-27 | Aquestive Therapeutics | Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis |
FDA applications (1)
| Application | Approved | Type | Applicant |
|---|---|---|---|
| NDA 212640 | 2019-11-22 | NDA | AQUESTIVE THERAPEUTICS INC |
Marketed products (1)
- EXSERVAN